title: Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.
abstract: The therapeutic landscape in advanced non-small-cell lung cancer (NSCLC) is rapidly changing. Never have so many changes of major importance occurred within so short a time. The present perspective describes this rapid evolution and resultant increasing complexity in the therapeutic decision-making process for the practicing oncologist.
authors.affiliation: University of California, Davis, Comprehensive Cancer Center, Sacramento, CA. Electronic address: drgandara@ucdavis.edu.
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.affiliation: University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Riess
authors.affiliation: University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.
authors.forename: Karen
authors.initials: K
authors.lastname: Kelly
authors.affiliation: University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.
authors.forename: Tianhong
authors.initials: T
authors.lastname: Li
authors.affiliation: University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.
authors.forename: Philip C
authors.initials: PC
authors.lastname: Mack
authors.affiliation: University of California, Davis, Comprehensive Cancer Center, Sacramento, CA.
authors.forename: Primo N
authors.initials: PN
authors.lastname: Lara
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases
keywords: Epidermal growth factor receptor; NSCLC; Targeted therapy; Therapeutic landscape; Tyrosine kinase inhibitor